Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by snuff133on Feb 03, 2021 8:40am
151 Views
Post# 32456450

RE:Ventripoint Diagnostics Removes All Debt From Balance Sheet,

RE:Ventripoint Diagnostics Removes All Debt From Balance Sheet,Dear Friend;
 
The attached NR will go out tomorrow morning.
 
The NR is straight forward but here is some background;
 
1. We did 3 rounds of convertible debentures, which all ended up in general security agreement for a total debt of $2.7M.  
2. We also issued warrants with these debentures which ended up at an exercise price of 10 cents.
3. The news release gives the details, but the good news is all the debt has been converted and the warrants have almost all been exercised.  The ones that are left are now subject to an accelerated expiry and must be exercised before March 5, 2021 (30 days).
4. I want to point out, we were forced to add the accelerated expiry clause but the Exchange when we repriced the warrants and it was triggered automatically.  Nothing we could do about it.
5. We have also had most of the warrants from the October 2019 equity round exercised at 11.5 cents.  There was no acceleration clause on this series of warrants, but I have asked warrantholders to exercise so we could have the cash and the runway it provides.  Most people were happy to accommodate us.
6. So we have 2-years of operating cash in the bank and will get additional cash ~$750,000 as the remaining warrants are exercised as well as sales revenue, government grants and subsides and other sources of income.
7. Given the volume of shares we have been trading (270M in last 4 months), any selling of stock from conversions and warrant exercises has been easily absorbed by the market.
8.  So there is really nothing significant to hold back the share price on good news.
9. We are making good progress on operations, but more about that in a future news release.
10. I want to thank all the people who bravely invested and re-invested in the company back in early February 2020, when things were particularly precarious.  I am delighted they have made a nice return in the last 12 months.  It is only the beginning.
 
The best part is that we can continue our quest to change cardiac diagnostics and care worldwide, thanks to your support and encouragement.
 
Regards,

<< Previous
Bullboard Posts
Next >>